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A meta‑analysis uncovers the first 
sequence variant conferring risk 
of Bell’s palsy
Astros Th. Skuladottir1*, Gyda Bjornsdottir1, Gudmar Thorleifsson1, G. Bragi Walters1,2, 
Muhammad Sulaman Nawaz1,2, Kristjan Helgi Swerford Moore1, Pall I. Olason1, 
Thorgeir E. Thorgeirsson1, Brynja Sigurpalsdottir1,3, Gardar Sveinbjornsson1, 
Hannes P. Eggertsson1, Sigurdur H. Magnusson1, Asmundur Oddsson1, Anna Bjornsdottir4, 
Arnor Vikingsson5, Olafur A. Sveinsson5, Maria G. Hrafnsdottir5, Gudrun R. Sigurdardottir4, 
Bjarni V. Halldorsson1, Thomas Folkmann Hansen6, Helene Paarup7, Christian Erikstrup8, 
Kaspar Nielsen9, Mads Klokker10, Mie Topholm Bruun7, Erik Sorensen10, Karina Banasik6, 
Kristoffer S. Burgdorf10, Ole Birger Pedersen11, Henrik Ullum10, Ingileif Jonsdottir1,2, 
Hreinn Stefansson1 & Kari Stefansson1,2
Bell’s palsy is the most common cause of unilateral facial paralysis and is defined as an idiopathic 
and acute inability to control movements of the facial muscles on the affected side. While the 
pathogenesis remains unknown, previous studies have implicated post‑viral inflammation and 
resulting compression of the facial nerve. Reported heritability estimates of 4–14% suggest a 
genetic component in the etiology and an autosomal dominant inheritance has been proposed. 
Here, we report findings from a meta‑analysis of genome‑wide association studies uncovering the 
first unequivocal association with Bell’s palsy (rs9357446‑A; P = 6.79 × 10−23, OR = 1.23; Ncases = 4714, 
Ncontrols = 1,011,520). The variant also confers risk of intervertebral disc disorders (P = 2.99 × 10−11, 
OR = 1.04) suggesting a common pathogenesis in part or a true pleiotropy.
Bell’s palsy, also known as idiopathic facial paralysis, is an acute or subacute weakness of the facial muscles 
innervated by the seventh cranial nerve (the facial nerve). Symptoms are usually unilateral although both sides 
can be affected. Although symptoms usually subside within one month, up to 30% of cases show delayed or 
incomplete recovery with mild to severe residual facial weakness, contracture, and/or hemifacial  spasm1. Other 
symptoms vary from person to person and may include mild facial pain, numbness or stiffness and headache. 
The annual incidence is about 20–30 cases per 100,000, with about 1 in 60 lifetime risk. The disorder usually 
occurs in individuals aged 15–40 and affects men and women  equally2. Risk factors include  hypertension3, 
 diabetes4,  immunosuppression5, Lyme  disease6, and in rare cases inflammatory demyelinating neuropathy such 
as Guillain-Barré  syndrome7.
While the exact etiology of Bell’s palsy is unknown, it has been suggested that the disorder is caused by inflam-
mation or compression of the seventh cranial  nerve6. The literature has highlighted several viral illnesses such 
as herpes simplex type 1, which has been detected in 31–79% of  cases8,9, human immunodeficiency  viruses10, 
varicella-zoster, and Epstein-Barr11. After a primary infection, these latent viruses reside in the geniculate gan-
glion or in lymphocytes. At times with e.g. stress, the viruses may be reactivated and cause local damage to the 
 myelin8. The two most common treatments are corticosteroids and antivirals. However, studies have found that 
antivirals alone are not helpful and antiviral treatment in combination with corticosteroids have conflicting 
 results12. Although the heritability has been estimated to be only 4–14%1,13, numerous familial cases have been 
reported.
Here, we report the first meta-analysis of genome-wide association studies (GWASs) of Bell’s palsy, combining 
data from Iceland (deCODE genetics), the UK (UK Biobank), Denmark (Danish Blood Donor Study [DBDS] 
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and Copenhagen Hospital Biobank [CHB]), and Finland (FinnGen), which uncovers an association with a 
common intergenic variant.
Results
Genome‑wide meta‑analysis. We performed a meta-analysis combining Bell’s palsy GWAS results 
for 30,341,632 variants from Iceland (Ncases = 290, Ncontrols = 342,122), the UK (Ncases = 2024, Ncontrols = 406,541), 
Denmark (Ncases = 1383, Ncontrols = 141,497), and Finland (Ncases = 1017, Ncontrols = 121,360). Bell’s palsy cases were 
assigned ICD-10 (G51.0) diagnoses by a physician in all study cohorts (Methods; demographics in Supplemen-
tary Table 1). Applying logistic regression, we identified an association with a common variant, rs9357446-A 
(Allele Frequency  [AF]ICE = 55.5%,  AFUK = 53.3%,  AFDEN = 52.7%,  AFFIN = 50.8%), that confers risk of Bell’s palsy 
(P = 6.79 × 10–23, Odds ratio [OR] = 1.23) (Table 1, Fig. 1, Supplementary Data). The full genotypic model does 
not significantly differ from the additive model (Pfull vs. additive = 0.19; Supplementary Fig. 1).
There is a small evidence of heterogeneity (P-het ≤ 0.05) describing a modest difference in the four datasets. 
Therefore, we applied a random-effects model which assumes that there may be different underlying true effects 
estimated in each dataset. The variant maintains a weighted Bonferroni significance (P = 6.83 × 10–23) based on 
predicted functional impact of the association signal.
The risk of developing Bell’s palsy is similar in all datasets (See P-het in Table 1, Fig. 2). The estimated genetic 
inflation is low for the datasets (Iceland = 1.03, UK = 1.01, Denmark = 1.00, Finland = 1.03) considering that both 
the Icelandic and the UK samples have a high number of related individuals. In Iceland, a large fraction of the 
population has participated in genetic studies and in the UK Biobank, ~ 30% of the participants have a relative 
of third degree or  closer14.
Based on the Icelandic data, twenty-two non-coding variants in the region correlate with rs9357446 (r2 > 0.2) 
and of those, eleven are highly correlated (r2 > 0.9; Fig. 3, Supplementary Table 2). A conditional analysis dem-
onstrates that the association of these variants with Bell’s palsy is accounted for by rs9357446, indicating one 
independent variant. The variant is not correlated (r2 < 0.2) with any known coding or structural variants.
We examined cis-eQTL in blood and adipose tissue in Iceland and did not find an association between 
rs9357446 and expression of nearby genes (Supplementary Note). The variant did not affect expression in any 
nearby genes in 18 other databases listed in Supplementary Table 3. We tested associations between rs9357446 
and 4792 plasma proteins measured in 35,559 Icelanders but did not find a significant association (Supplementary 
Note). We also measured methylation of CpGs in a 2000 Bp window around rs9357446. A CpG methylation at 
Table 1.  Association of a novel, genome-wide significant variant identified in the Bell’s palsy meta-analysis. 
Significance levels and effects are shown for the combined analysis. EA effect allele, OA other allele, EAF effect 
allele frequency, OR odds ratio, CI confidence interval, P-het P-value for test of heterogeneity between Iceland, 












chr6:44,479,861 rs9357446 A/G 53.1 [CDC5L] Intergenic 1.23 (1.18, 1.28) 6.79 × 10
–23 0.048 6.83 × 10–23
Figure 1.  Manhattan plot for the Bell’s palsy meta-analysis. One genome-wide significant locus was detected. 
The − log10 P-values (y-axis) are plotted for each variant against their chromosomal position (x-axis). The red 
line denotes the significance threshold for intergenic variants, P ≤ 7.4 × 10–10. P-values are two sided and derived 
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chr6:44,480,140 is slightly increased in rs9357446-A carriers (N = 1236, P = 0.024). However, this CpG is generally 
methylated and a slight increase in methylation is not likely to have any biological effect.
We performed genetic correlation analyses using the Bell’s palsy meta-analysis and 600 GWASs from the 
UK  Biobank15. The Bell’s palsy meta-analysis associates with seven lifestyle traits (P ≤ 0.05/600 = 8.33 × 10–5; 
Supplementary Table 4) such as number of treatments or medications taken (rG = 0.41, P = 1.55 × 10–8) and poor 
health (rG =  − 0.36, P = 1.79 × 10–7).
rs9357446‑A and associations with other phenotypes. The variant has previously been reported 
to associate with decreased lung function measured by forced vital capacity (FVC)16. This finding replicates in 
the Icelandic dataset (P = 0.0145, β =  − 0.037). We did not find association with other lung related phenotypes 
including asthma, chronic obstructive pulmonary disease, or tuberculosis combining the Icelandic, UK and 
Danish data in meta-analyses and we did not find associations with other reported risk factors such as hyperten-
sion and type 1 diabetes (Supplementary Table 5). In a meta-analysis of 58,854 cases and 922,958 controls from 
Iceland, the UK, Denmark, and Finland, rs9357446-A associates with intervertebral disc disorders (IDD [ICD-
10: M51]; P = 2.99 × 10–11, OR = 1.04; unpublished work by Bjornsdottir G et al.). rs9357446-A is among the top 
variants at the locus for IDD (Supplementary Fig. 3).
Figure 2.  Forest plot of the observed risk of Bell’s palsy for individuals carrying rs9357446-A in each study 
sample. The number of Bell’s palsy cases in each sample is shown in the second column.
Figure 3.  Regional visualization of the Bell’s palsy meta-analysis. The leading variant is colored in black. Other 
variants are colored by the degree of correlation (r2) with rs9357446. The − log10 P-values on the left y-axis (two-
sided logistic regression) are plotted for each variant against their chromosomal position (x-axis). The right 
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Discussion
The precise pathophysiology of Bell’s palsy is unknown and biologically targeted treatment is lacking. The aim 
of the study was to search for variations in the human genome affecting risk of Bell’s palsy and thus use genetics 
to uncover biological underpinnings of this somewhat mysterious disease. Here, we report the first unequivocal 
association between Bell’s palsy and a sequence variant, rs9357446-A (P = 6.79 × 10–23, OR = 1.23), in a meta-
analysis of four study cohorts.
While rs9357446-A confers risk of Bell’s palsy, it also confers low risk of IDD as well as reduced lung function 
measured by decreased  FVC16 suggesting shared etiology of these diverse diseases that are all but certain to dif-
fer in the pathogenesis. The common variant at 6p21.1 is intergenic. Nearby genes are LOC105375075, CDC5L, 
MIR4642, SPATS1, AARS2, TCTE1, TMEM151B, and SLC35B2. Our transcript- and proteomics analyses did 
not pinpoint a Bell’s palsy gene at this locus. Although uncorrelated with rs9357446 (r2 < 0.2), several sequence 
variants in the closest gene, cell division cycle 5 like (CDC5L), have been found to associate with related phe-
notypes, including  osteoarthritis17, bone  density18, ossification of the  spine19, and lung function measured by 
FVC and forced expiratory  volume16. Another potential candidate at the locus, SLC35B2, is a key component of 
a protein sulfation pathway where it plays a part in modifying C–C Motif Chemokine Receptor 5 (CCR5), that 
is one of HIV’s host proteins for entry into the  cell20. Several other studies point to the importance of CCR5 in 
determining disease severity of other viral infections in animal  models21,22. In addition, SLC35B2 is involved in 
proteoglycan synthesis. Cartilage is particularly rich in proteoglycans, and changes in the structure and com-
position of glycosaminoglycans, forming the sugar chain attached to the protein core of proteoglycans, have 
been found in osteoarthritis. Mutations in slc35b2 in zebrafish have been shown to cause deformation of the 
craniofacial  skeleton23.
Bell’s palsy is still idiopathic since we do not know what causes it; there are no biomarkers to support the diag-
nosis and the diagnosis requires exclusion of any other cause of facial  paralysis24. In Bell’s palsy, a viral infection 
is considered one of the possible  causes8. The main treatment is corticosteroids, which supports the theory of 
edema induced entrapment neuropathy. The facial nerve traverses through the temporal bone (the facial canal) 
and branches to innervate the facial muscles. The narrowest part of the canal, the labyrinthine segment, is where 
most cases of compression occur, which may result in ischemic neuropathy of the facial  nerve25.
We were unable to determine a gene at 6p21.1 involved in Bell’s palsy pathology. However, the association of 
rs9357446-A with IDD brings up the possibility that the variant may confer risk of Bell’s palsy through an effect 
on cartilage and bone development. Alternatively, the association between Bell’s palsy, IDD, and reduced lung 
function may be a result of a true pleiotropy. Although more studies are needed, the identification of this variant 
contributes to the limited understanding of Bell’s palsy.
Methods
Ethics statement. All Icelandic data were collected through studies approved by the National Bioethics 
Committee (NBC; License #VSN-12-162 with amendments) following review by the Icelandic Data Protection 
Authority. Participants donated blood or buccal samples after signing a broad informed consent allowing the 
use of their samples and data in all projects at deCODE genetics approved by the NBC. All personal identifiers 
of the participants’ data were encrypted by a third-party system, approved and monitored by the Icelandic Data 
Protection Authority.
The UK Biobank data were obtained under application number 24898. All phenotype and genotype data 
were collected following an informed consent obtained from all participants. The North West Research Ethics 
Committee reviewed and approved UK Biobank’s scientific protocol and operational procedures (REC Reference 
Number: 06/MRE08/65).
The Danish Data Protection Agency (2007-58-0015) and the National Committee on Health Research Ethics 
(NVK-1700407) approved the genetic study on Danish Blood Donor Study (DBDS). The data requested for this 
study was approved by the DBDS steering committee. Samples from the Copenhagen Hospital Biobank (CHB) 
were included as part of the study on pain related diseases under the genetics of pain and degenerative muscu-
loskeletal disease protocol (NVK-1803012).
Samples and phenotype data were collected from the Finnish biobanks and the national health registers, 
respectively, for the FinnGen database. The Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital 
District evaluated and approved the FinnGen research project. The project complies with existing legislation 
(in particular the Biobank Law and the Personal Data Act). The official data controller of the study is University 
of Helsinki.
Study subjects. To identify Bell’s palsy cases in Iceland, we searched for patients over the age of 18 with 
International Classification of Diseases (ICD-10) diagnosis code G51.0 and ICD-9 code 351.0 at the National 
University Hospital of Iceland and all Icelandic primary and secondary care centers. Records spanned from 1983 
to 2019.
The UK Biobank study is a large prospective cohort study of ~ 500,000 individuals in the age range of 40–69 
from across the UK. Extensive phenotype and genotype data have been collected for participants, including ICD 
diagnosis codes. Bell’s palsy diagnoses in the UK Biobank were obtained by searching for cases with ICD-10 
code G51.0 from UK Biobank General Practice clinical event records (Field ID 42,040) and hospital diagnoses 
(Field ID 41,270 and 41,271). Only individuals of Caucasian ancestry were included.
The CHB is a research bank, which contains left over samples from diagnostic procedures on in- and out-
patients in hospitals in the Danish Capital Region. The DBDS GWAS study is a nationwide prospective cohort 
study of ~ 100,000 blood donors. We applied for ICD-10 code G51.0 from CHB and  DBDS26. Genetic ancestry 
quality control was performed in two stages. Firstly, ADMIXTURE v1.2327 was run in supervised mode with 
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1000G populations CEU, CHB, and  YRI28 as training samples and Danish individuals as test samples. Input 
data for ADMIXTURE had long-range LD regions  removed29 and was then LD-pruned with PLINK v.190b3a30 
–indep-pairwise 200 25 0.3. Danish samples with less than 0.9 assigned CEU ancestry were excluded. In the 
second stage, remaining Danish samples were projected onto a principal component analysis (PCA), calculated 
with in-house tools on an in-house European reference panel. The UMAP package in  R31 was used to reduce the 
coordinates of test samples on 20 principal components to two dimensions. Additional European samples not in 
the original reference, were also projected onto the PCA and UMAP to help identify the ancestries represented in 
clusters. A polygon informed by visual inspection was drawn to include all samples with very similar ancestries 
to the main Danish cluster.
The phenotype data from the FinnGen study was produced from several national health registries. All Bell’s 
palsy cases were diagnosed by a physician and categorized using ICD-10 code G51.0, ICD-9 code 351.0, and 
ICD-8 code 350. The summary statistics for available phenotypes, including Bell’s palsy, were imported on June 
16th 2020 from a source available to consortium partners (version 3; http://r3.finng en.fi).
We combined 290 cases and 342,122 controls from Iceland, 2024 cases and 406,541 controls from the UK, 
1383 cases compared to 41,497 patients with other pain related disorders (CHB) and 100,000 controls (DBDS) 
from Denmark, and 1017 cases and 121,360 controls from Finland; in total, 4714 cases and 1,011,520 controls.
Genotyping. The preparation of samples and the whole-genome sequencing of 49,962 Icelanders has 
been described in detail  elsewhere32,33. In short, 37.6 million high-quality sequence variants were identified 
by sequencing 49,962 Icelanders using GAIIx, HiSeq, HiSeqX, and NovaSeq Illumina technology to a mean 
depth of at least 17.8 × . SNPs and indels were identified and their genotypes called using joint calling with 
 Graphtyper34. Additionally, over 165,000 Icelanders (including all sequenced Icelanders) have been genotyped 
using various Illumina SNP chips and phased using long-range  phasing35, which allows for improving genotype 
calls using the information about haplotype sharing. The genotypes of the high-quality sequence variants were 
imputed into the chip-typed  Icelanders36. To increase the sample size and power to detect associations, the 
sequence variants were also imputed into relatives of the chip-typed using genealogic information. All the tested 
variants had imputation information over 0.8.
The UK Biobank samples were genotyped with a custom-made Affymetrix chip, UK BiLEVE Axiom in the 
first 50,000  individuals37, and the Affymetrix UK Biobank Axiom  array38 in the remaining participants. Imputa-
tion was performed by the Wellcome Trust Centre for Human Genetics using a combination of the Haplotype 
Reference  Consortium39, UK10K haplotype  resources40, and 1000Genomes phase 3  panels28. A total of 96 million 
variants have been imputed.
Over 332,000 samples from the CHB and DBDS together with ~ 238,000 genotyped samples from North-
western Europe were long-range phased using  Eagle241. Samples and variants with less than 98% yield were 
excluded. We used the same methods as used for the Icelandic  data32,35 to create a haplotype reference panel 
by phasing the whole-genome sequence genotypes (N = 8635) using the phased chip data (N = 332,949), and to 
impute the genotypes from the haplotype reference panel into the phased chip data. Whole genome sequencing, 
chip-typing, quality control, and the subsequent imputation from which the data for this analysis were generated 
was performed at deCODE genetics.
A custom-made FinnGen ThermoFisher Axiom array (> 650,000 SNPs) was used to genotype ~ 135,600 
FinnGen samples at Thermo Fisher genotyping service facility in San Diego. Imputation was performed using 
the Finnish population specific WGS backbone. More than 16 million variants have been imputed.
Association analysis. We performed logistic regression using the Icelandic, UK, and Danish data and 
combined the results with imported association results from Finland to test for association between sequence 
variants and Bell’s palsy using software developed at deCODE  genetics32. We used LD score regression to account 
for distribution inflation due to cryptic relatedness and population stratification in the Icelandic, UK, and Dan-
ish  data42. In the Icelandic association analysis, we adjusted for sex, county of origin, current age or age at death 
(first and second order term included), blood sample availability for the individual, and an indicator function 
for the overlap of the lifetime of the individual with the time span of phenotype collection. In the UK association 
analysis, we adjusted for sex, age, and the first 40 principal components to adjust for population stratification. 
In the Danish association analysis, we adjusted for sex, whether the individual had been chip-typed and/or 
sequenced, and the first 20 principal components. The FinnGen association analysis was adjusted for sex, age, 
the genotyping batch, and the first 10 principal components.
For the meta-analysis, we used a fixed-effects inverse variance  method43 to combine the results from the four 
study groups in which the groups were assumed to have a common OR but allowed to have different population 
frequencies for alleles and genotypes. Variants with imputation information below 0.8 were excluded from the 
analysis. Sequence variants were mapped to NCBI Build38 and matched on position and alleles to harmonize 
the four datasets. We estimated the genome-wide significance threshold and corrected for multiple testing with 
a Bonferroni procedure weighted for variant classes and predicted functional  impact44. A likelihood ratio test 
was performed for the genome-wide significant variant to test the heterogeneity of the effect estimate in the four 
datasets. The null hypothesis is that the effects are the same in all datasets and the alternative hypothesis is that 
the effects differ between datasets.
Conditional analysis was performed to identify the most likely causal variant at the locus and to identify any 
secondary signals. We used the true genotypes of participants in the study from Iceland, the UK, and Denmark. 
LD between variants was estimated using a set of 8700 WGS Icelanders and was restricted to variants within 
one Mb from the index variant.
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Genetic correlation analyses between the Bell’s palsy meta-analysis and 600 published GWAS traits 
(P ≤ 0.05/600 = 8.33 × 10–5) from the UK  Biobank15 with effective sample size over 5000 were performed using 
LDSC  method42,45. The LDSC method suggests minimal effective sample size of 5000 for a GWAS trait to get 
unbiased estimates of genetic correlation and heritability. Since the published GWAS studies used in the analysis 
have Caucasian ancestry, we used pre-computed LD scores from a 1000 genome panel with  r2 from HapMap3 
excluding HLA region. The HLA region was excluded for its complex genetic pattern and associations with wide 
number of traits. Moreover, the default parameters of LDSC method were used to compute genetic correlation 
and heritability estimates.
Transcriptomics. RNA sequencing of 14,248 genes was performed on the whole blood of 13,175 Iceland-
ers and of 9396 genes on the subcutaneous adipose tissue from 700 Icelanders. Gene expression was computed 
based on personalized transcript  abundances46. Association between variants and gene expression was estimated 
using a generalized linear regression, assuming additive genetic effect and quantile normalized gene expression 
estimates, adjusting for measurements of sequencing artefacts, demographic variables, blood composition, and 
hidden  covariates47.
Proteomics. We used SomaLogic SOMAscan proteomics assay to test the association of the sequence vari-
ant with protein levels in plasma. The assay scanned 4983 proteins in samples from 35,559 Icelanders with 
genetic information available at deCODE genetics. Plasma protein levels were standardized and adjusted for year 
of birth, sex, and year of sample collection (2000–2019).
Methylomics. We performed whole-methylome-sequencing on 4133 samples using ONT Ligation Sequenc-
ing Kit (SQK-LSK108) or Rapid Sequencing Kit (SQK-RAD003)48. MinION and PromethION devices with 
FLO-106/R9.4 flow cells were used for base calling. Methylation on CpGs was called using Nanopolish (version 
0.6.1)49.
 Data availability
The sequence variants from the Icelandic population whole-genome sequence data have been deposited at the 
European Variant Archive under accession code PRJEB15197. The authors declare that the data supporting the 
findings of this study are available within the article, its Supplementary Information file, and upon reasonable 
request.
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